BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BSX - US1011371077 - Common Stock
88.4 EUR
+2.6 (+3.03%)
Overall 1BSX gets a fundamental rating of 5 out of 10. We evaluated 1BSX against 63 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of 1BSX get a neutral evaluation. Nothing too spectacular is happening here. 1BSX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
1BSX had positive earnings in the past year.
1BSX had a positive operating cash flow in the past year.
Of the past 5 years 1BSX 4 years were profitable.
In the past 5 years 1BSX always reported a positive cash flow from operatings.
1.2 Ratios
1BSX has a Return On Assets of 6.03%. This is in the better half of the industry: 1BSX outperforms 69.84% of its industry peers.
Looking at the Return On Equity, with a value of 11.17%, 1BSX is in the better half of the industry, outperforming 69.84% of the companies in the same industry.
With a decent Return On Invested Capital value of 7.66%, 1BSX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1BSX is below the industry average of 9.33%.
The last Return On Invested Capital (7.66%) for 1BSX is above the 3 year average (6.54%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
Looking at the Profit Margin, with a value of 13.54%, 1BSX is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
In the last couple of years the Profit Margin of 1BSX has declined.
The Operating Margin of 1BSX (18.69%) is better than 80.95% of its industry peers.
In the last couple of years the Operating Margin of 1BSX has remained more or less at the same level.
Looking at the Gross Margin, with a value of 68.30%, 1BSX is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
1BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 1BSX is destroying value.
The number of shares outstanding for 1BSX has been increased compared to 1 year ago.
1BSX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1BSX has a worse debt to assets ratio.
2.2 Solvency
1BSX has an Altman-Z score of 5.67. This indicates that 1BSX is financially healthy and has little risk of bankruptcy at the moment.
1BSX's Altman-Z score of 5.67 is amongst the best of the industry. 1BSX outperforms 88.89% of its industry peers.
The Debt to FCF ratio of 1BSX is 3.33, which is a good value as it means it would take 1BSX, 3.33 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 1BSX (3.33) is better than 73.02% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that 1BSX is not too dependend on debt financing.
The Debt to Equity ratio of 1BSX (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.67 |
ROIC/WACC0.94
WACC8.18%
2.3 Liquidity
A Current Ratio of 1.37 indicates that 1BSX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.37, 1BSX perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
A Quick Ratio of 0.82 indicates that 1BSX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.82, 1BSX is doing worse than 63.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
The Revenue has grown by 21.62% in the past year. This is a very strong growth!
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, 1BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.40% on average per year.
Based on estimates for the next years, 1BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.12% on average per year.
EPS Next Y20.01%
EPS Next 2Y17.07%
EPS Next 3Y15.64%
EPS Next 5Y14.4%
Revenue Next Year19.72%
Revenue Next 2Y15.31%
Revenue Next 3Y13.68%
Revenue Next 5Y12.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 34.67, 1BSX can be considered very expensive at the moment.
1BSX's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.15. 1BSX is valued slightly more expensive when compared to this.
1BSX is valuated quite expensively with a Price/Forward Earnings ratio of 29.75.
1BSX's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 36.12. 1BSX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.67 | ||
| Fwd PE | 29.75 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1BSX is valued a bit more expensive than the industry average as 61.90% of the companies are valued more cheaply.
1BSX's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.53 | ||
| EV/EBITDA | 34.09 |
4.3 Compensation for Growth
1BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
1BSX has a very decent profitability rating, which may justify a higher PE ratio.
1BSX's earnings are expected to grow with 15.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.73
PEG (5Y)3.63
EPS Next 2Y17.07%
EPS Next 3Y15.64%
5. Dividend
5.1 Amount
1BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BSX (11/17/2025, 7:00:00 PM)
88.4
+2.6 (+3.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap130.99B
Revenue(TTM)19.35B
Net Income(TTM)2.50B
Analysts86.34
Price Target110.77 (25.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)3.47%
PT rev (3m)5.89%
EPS NQ rev (1m)-0.04%
EPS NQ rev (3m)-0.04%
EPS NY rev (1m)0%
EPS NY rev (3m)2.19%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.67 | ||
| Fwd PE | 29.75 | ||
| P/S | 8.2 | ||
| P/FCF | 43.53 | ||
| P/OCF | 35.4 | ||
| P/B | 6.76 | ||
| P/tB | N/A | ||
| EV/EBITDA | 34.09 |
EPS(TTM)2.55
EY2.88%
EPS(NY)2.97
Fwd EY3.36%
FCF(TTM)2.03
FCFY2.3%
OCF(TTM)2.5
OCFY2.83%
SpS10.78
BVpS13.07
TBVpS-1.7
PEG (NY)1.73
PEG (5Y)3.63
Graham Number27.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.67 |
F-Score5
WACC8.18%
ROIC/WACC0.94
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y20.01%
EPS Next 2Y17.07%
EPS Next 3Y15.64%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year19.72%
Revenue Next 2Y15.31%
Revenue Next 3Y13.68%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI.
What is the valuation status of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a valuation rating of 2 / 10 to BOSTON SCIENTIFIC CORP (1BSX.MI). This can be considered as Overvalued.
What is the profitability of 1BSX stock?
BOSTON SCIENTIFIC CORP (1BSX.MI) has a profitability rating of 6 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (1BSX.MI) is 34.67 and the Price/Book (PB) ratio is 6.76.
Can you provide the financial health for 1BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (1BSX.MI) is 4 / 10.